Crizotinib (PF-02341066)

For research use only. Not for use in humans.

Pfizer辉瑞授权 目录号:S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) 克唑替尼是一种有效的c-MetALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂,其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1812.55 现货
RMB 900.49 现货
RMB 1372.81 现货
RMB 4681.47 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Crizotinib (PF-02341066)发表文献255篇:

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述 Crizotinib (PF-02341066) 克唑替尼是一种有效的c-MetALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂,其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。
靶点
ROS1 [6]
(Cell-free assay)
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
<0.025 nM(Ki) 11 nM 24 nM
体外研究

PF-2341066作用于mIMCD3小鼠和MDCK犬上皮细胞,作用于c-Met磷酸化作用时具有相似效果,IC50分别为5 nM 和20 nM。PF-2341066作用于表达c-Met ATP-结合位点突变型V1092I 或H1094R或 P-环突变 M1250T 的NIH3T3 细胞,具有相似的活性,且活力增高,IC50分别为19 nM,2 nM 和15 nM,而作用于表达野生型受体的NIH3T3 细胞时,IC50为13 nM。[1] 相反, 观察到PF-2341066作用于表达c-Met活化环突变型Y1230C 和Y1235D的细胞时,与作用于野生型受体相比,效果发生显著改变,IC50分别为127 nM 和92 nM。PF-2341066 作用于分别表达内源性c-Met 突变体R988C和 T1010I 的NCI-H69 和HOP92 细胞,也有效抑制c-Met 磷酸化, IC50分别为13 nM 和16 nM。与作用于c-Met相比,PF-2341066作用于VEGFR2 和PDGFRβ RTKs, 选择性高1000多倍,作用于IRK和Lck选择性高250多倍,作用于Tie2, TrkA,和TrkB选择性高40到60倍。PF-2341066 作用于RON和 Axl RTKs时选择性为20到30倍。相反,PF-2341066 作用于表达ALK RTK 的核磷蛋白 (NPM)- 间变性淋巴瘤激酶(ALK) 致癌融合突变体和 KARPAS299人间变性大细胞淋巴瘤(ALCL)细胞系时具有相近的IC50值,为24 nM。PF-2341066抑制c-Met依赖的癌细胞的肿瘤表现型,和内皮细胞的血管生成表现型。PF-2341066抑制人GTL-16胃癌细胞生长,IC50为9.7 nM。PF-2341066诱导 GTL-16细胞凋亡,IC50 为8.4 nM。PF-2341066 抑制HGF刺激的人NCI-H441肺癌细胞迁移和入侵,IC50分别为11 nM 和6.1 nM。PF-2341066抑制 MDCK细胞散射,IC50为16 nM。PF-2341066 抑制HGF-刺激的c-Met磷酸化,细胞存活,和Matrigel入侵,IC50分别为11 nM, 14 nM和35 nM。此外, PF-2341066抑制纤维蛋白胶中的血清刺激的 HMVEC分支小管形成 (形成血管)。[1] PF-2341066 作用于Karpas299 或SU-DHL-1 ALCL细胞,也有效抑制 NPM-ALK磷酸化,IC50 为24 nM。PF-2341066 有效抑制细胞增殖,伴随着使细胞周期停在G(1)-S期,且诱导 ALK阳性的 ALCL 细胞凋亡,IC50为30 nM, 但是作用于ALK阴性的淋巴瘤细胞则无效果。 [2] 此外, PF-2341066 抑制骨肉瘤的一些活动行为,及其肿瘤生长 (例如,增殖和存活)和转移 (例如,入侵和形成克隆)。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 MmrLR5l1d3SxeHnjJGF{e2G7 NWfqW2NOPDhiaB?= M2PEU2ROW09? MoXsR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCwMlYzKM7:TR?= M1zYU|IyPTd{NUi5
BAF3 NGL2UnBEgXSxdH;4bYMhSXO|YYm= NFjteJQ1QCCq M4DGNWROW09? M1HUPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugUFEyQT[PIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNk4zKM7:TR?= MVWyNVU4OjV6OR?=
BAF3 MVLDfZRwfG:6aXOgRZN{[Xl? M1fRZ|Q5KGh? MX;EUXNQ MkjYR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKHerdHigTWM2OCCxZjCwMlI5KM7:TR?= Mln4NlE2PzJ3OEm=
Kelly NI[wc3pEgXSxdH;4bYMhSXO|YYm= MVfEUXNQ NGTEdXpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBM\WyueTDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IIfpeIghUUN3MDDv[kAxNjR{IN88US=> NEXNSpQzOTV5MkW4PS=>
SH-SY5Y MXXDfZRwfG:6aXOgRZN{[Xl? NIPqS|RFVVOR NUToVGxGS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0hvU2m1XUBk\WyuczDlfJBz\XO|aX7nJGFNUyCIMUG3OGwhdXW2YX70JJdqfGhiSVO1NEBw\iByLkWzJO69VQ>? M4DDVFIyPTd{NUi5
SMS-KCN NGPHTFJEgXSxdH;4bYMhSXO|YYm= M3r1dWROW09? M3H3WGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNOWy2NQ16gZ4VtdHNiZYjwdoV{e2mwZzDBUGshWjF{N{XRJI12fGGwdDD3bZRpKEmFNUCgc4YhOC57MTFOwG0> M3rUSFIyPTd{NUi5
BAF3 M1zoemN6fG:2b4jpZ{BCe3OjeR?= NFnBWmk1QCCq NFLWZ2FFVVOR NWPRWWNTS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIGTlcE1CVEtid3n0bEBKSzVyIH;mJFAvOTlizszN MljvNlE2PzJ3OEm=
3T3 NXS4cnpMTnWwY4Tpc44hSXO|YYm= NVrTdJdbOSCq M3jVN2ROW09? NF[zSIlKdmirYnn0bY9vKG:oIGLPUkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? MXSyNVgyOjRzNB?=
3T3-E NETZclFHfW6ldHnvckBCe3OjeR?= MUKxJIg> M3\HSmROW09? NG\kcYdKdmirYnn0bY9vKG:oIGTJSVIh[XO|ZYPz[YQh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNES4JO69VQ>? M{O1VlIyQDF{NEG0
A549 NH:4enBMcW6jc3WgRZN{[Xl? MoT6NUBp NHuwZ2hFVVOR MoLOTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCClLV3FWEBscW6jc3Wg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTGdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODhizszN MX:yNVgyOjRzNB?=
BAF3-BCL MnzDSpVv[3Srb36gRZN{[Xl? M1jYdlEhcA>? NFS1SHVFVVOR M17jbGlvcGmkaYTpc44hd2ZiQVLMJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iBzLkG1PUDPxE1? NH\Cc|gzOThzMkSxOC=>
HEK293 NX;MTJZMTnWwY4Tpc44hSXO|YYm= NEj5d3gyKGh? NFz4UmdFVVOR MlSzTY5pcWKrdHnvckBw\iCDWFygZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMkm0JO69VQ>? MXqyNVgyOjRzNB?=
HEK293 NXz6dpRUTnWwY4Tpc44hSXO|YYm= NFvuT5gyKGh? NEDZZVRFVVOR Mn7tTY5pcWKrdHnvckBw\iCLUjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi56OEeg{txO MWqyNVgyOjRzNB?=
Jurkat NXj4SIVYTnWwY4Tpc44hSXO|YYm= NX\yUYJSOSCq MmXzSG1UVw>? NVnuUmhZUW6qaXLpeIlwdiCxZjDMR2sh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEKuO|QyKM7:TR?= NW[4OGxtOjF6MUK0NVQ>
KARPAS299 Mn7XT4lv[XOnIFHzd4F6 NVruTIdnOSCq MmL0SG1UVw>? Mn34TY5pcWKrdHnvckBw\iCDTFugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO MVGyNVgyOjRzNB?=
PAE NVTPbZV[TnWwY4Tpc44hSXO|YYm= M4PTe|EhcA>? NI\mNnpFVVOR M2SyfWlvcGmkaYTpc44hd2ZiVGLLRkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6zPVkh|ryP NXPjdmVKOjF6MUK0NVQ>
BAF3 MVrGeY5kfGmxbjDBd5NigQ>? MkTZNk0{KGR? NEPvTINFVVOR NI[4UXBKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDpcpN2dGmwIILlZ4VxfG:{IHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOS54NEOg{txO NUnNUVR7OjN5NEKyOVI>
KARPAS299 NFKyOXpEgXSxdH;4bYMhSXO|YYm= NV3KOodHOi1|IHS= NIWzdlVFVVOR MXnJR|UxRTBwME[0NkDPxE1? NH\YcpkzOzd2MkK1Ni=>
EBC1 NV;4PGluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYS3NkBp MnPPSG1UVw>? MmXGTWM2OD1yLkCyN{DPxE1? NUTyZVlzOjN7OUOzNlg>
HCT116 NYPZXpA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXyO|IhcA>? MWHEUXNQ MUTJR|UxRTF2LkiyJO69VQ>? M4C2dVI{QTl|M{K4
MCF7 NXm4S|d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPXUpZ1PzJiaB?= NEPwbY9FVVOR Ml7HTWM2OD17LkW4JO69VQ>? Mlf1NlM6QTN|Mki=
MDA-MB-231 NXP1blVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfvO|IhcA>? Mmj3SG1UVw>? MofDTWM2OD1zMD64JO69VQ>? Mn;yNlM6QTN|Mki=
MKN45 NWjTUFd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH6emp5PzJiaB?= M3LzdWROW09? MX7JR|UxRTBwMEGzJO69VQ>? NVfYUlB2OjN7OUOzNlg>
NCI-H441 NVLUcmI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjycY1YPzJiaB?= NXPJPW96TE2VTx?= M4LlOGlEPTB;MUeuNlUh|ryP M2f6WVI{QTl|M{K4
NCI-H661 NUnOOZB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXOO|IhcA>? MULEUXNQ MYXJR|UxRTFzLkS3JO69VQ>? MY[yN|k6OzN{OB?=
SK-MEL-28 M3PnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrwbW44OiCq MUPEUXNQ MnzsTWM2OD1zMD65O{DPxE1? NF72N|AzOzl7M{OyPC=>
SKOV3 M1K3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlyyO|IhcA>? NF7F[2hFVVOR NY\0U2ltUUN3ME2xNk45PSEQvF2= NXP0W41QOjN7OUOzNlg>
SNU5 NYXlRWVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj4cJA4OiCq NUjX[ZdnTE2VTx?= NWO5UJE1UUN3ME2wMlAyPiEQvF2= NF:5RmgzOzl7M{OyPC=>
NCI-H2228 MoDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7kZ3NrPzJiaB?= MVTEUXNQ Mon3TY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTF6IN88US=> Ml3wNlQ1OzJ7MEm=
NCI-H3122 NG\E[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvRVo04OiCq NWm3WpVRTE2VTx?= Mo\MTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTB6IN88US=> MWeyOFQ{OjlyOR?=
NCI-H3122 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVK3NkBp MUnEUXNQ MVrJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDHNVI3QUFibYX0ZY51KHerdHigTWM2OCCxZjCwMlYzOyEQvF2= NGTGOG4zPDR|MkmwPS=>
NCI-H3122 M2nqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT1bpROPzJiaB?= NV7pXnFRTE2VTx?= MmnvTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugUFEyQT[PIH31eIFvfCC5aYToJGlEPTBib3[gNE45OzhizszN MnjlNlQ1OzJ7MEm=
NIH-3T3 M3Xlc2tqdmG|ZTDBd5NigQ>? NE\W[oEyKGh? NIrPToVFVVOR MV3Jcohq[mm2aX;uJI9nKGi3bXHuJJdqdGRidInw[UBGVUx2LX\1d4VlKEGOSzDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMheGixc4Doc5J6dGG2ZXSgRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkC4JO69VQ>? NET6WWQzPDR|MkmwPS=>
NIH-3T3 NHvB[FZMcW6jc3WgRZN{[Xl? NYPj[GJGOSCq M1HpOWROW09? NVKydIdbUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJ4OVGgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NFUh|ryP M{HSeVI1PDN{OUC5
NIH-3T3 Ml;GT4lv[XOnIFHzd4F6 MnH0NUBp NGezfZlFVVOR NH;MS2JKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJHMyOjB4WTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLk[yOkDPxE1? MoDFNlQ1OzJ7MEm=
NIH-3T3 MlT2T4lv[XOnIFHzd4F6 MX2xJIg> NWXRN5p[TE2VTx?= MUTJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVk3VSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjh2MzFOwG0> MlHHNlQ1OzJ7MEm=
NIH-3T3 NFLifpVMcW6jc3WgRZN{[Xl? NHLPbZEyKGh? NX\6XVNVTE2VTx?= Ml7jTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE2OlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5yMk[g{txO MYeyOFQ{OjlyOR?=
BAF3 M3z4bGZ2dmO2aX;uJGF{e2G7 MVy3NkBp MXjEUXNQ NFnrTXBKdmirYnn0bY9vKG:oIF7QUU9CVEtidILhcpNn\WO2ZXSgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yNUGg{txO MYqyOFQ3QDZ|Mh?=
BAF3 M3z0eGN6fG:2b4jpZ{BCe3OjeR?= MXG3NkBp MVzEUXNQ NFvPc2JKSzVyPUCuPVgh|ryP MnrNNlQ1Pjh4M{K=
NIH-3T3 MnjFT4lv[XOnIFHzd4F6 NXX4[JZMOSCq MWXJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIF[xNVc1VCCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjF4NTFOwG0> NULZSXVkOjR6MUmxNVY>
NIH-3T3 MV3LbY5ie2ViQYPzZZk> NEW1cXEyKGh? NUHMW|NiUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BEOTF3NmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD60O|gh|ryP NFj5NXQzPDhzOUGxOi=>
NIH-3T3 NVLxOJBuU2mwYYPlJGF{e2G7 NHvlNZgyKGh? MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlAzWiCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjF2ODFOwG0> MXWyOFgyQTFzNh?=
NIH-3T3 NUTKU3E5U2mwYYPlJGF{e2G7 NF3KdnoyKGh? MXzJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIEGxOVFVcW6|IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDNwMEO5JO69VQ>? MnO4NlQ5OTlzMU[=
KARPAS299 NVzUVnFJU2mwYYPlJGF{e2G7 NXL3WZlSQTBibXnu NHzHVYxFVVOR MmiwTY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO M13iZ|I1QTByN{Ww
MKN 45 M1fYPWtqdmG|ZTDBd5NigQ>? NH3SUYYyKGh? M4TnfWROW09? MnviTY5pcWKrdHnvckBw\iClLV3leEBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO NFXB[nozPDlyMEe1NC=>
A549 MnjUR5l1d3SxeHnjJGF{e2G7 MU[0PEBp M4jQWmROW09? NGnsOZFKSzVyIH;mJFQvODh2IN88US=> MVSyOFkxODh|MB?=
NCI-H1975 NFXEXopEgXSxdH;4bYMhSXO|YYm= MmHHOFghcA>? MXrEUXNQ M4jVdmlEPTBib3[gO{42PTFizszN NYjYNXl[OjR7MEC4N|A>
NCI-H1993 MkS4R5l1d3SxeHnjJGF{e2G7 NUfIN|c6PDhiaB?= NUTKS4RJTE2VTx?= MXzJR|UxKG:oIECuNFYyKM7:TR?= MUiyOFkxODh|MB?=
NCI-H1993 NV;DVo9wSXCxdH;zbZMhSXO|YYm= NWn1Oo1XOSEQvF2= NVL0VXRzOjRiaB?= NF7oVWFFVVOR M{LnN4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= NWD1ToZWOjR7MEC4N|A>
NIH-3T3 MXHDfZRwfG:6aXOgRZN{[Xl? NEj0RpY1QCCq MV7EUXNQ MYPJR|UxKG:oIECuN|Y1KM7:TR?= M1eyU|I1QTByOEOw
EBC1 M3;rbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M335O|czKGh? MXfEUXNQ MoXlTWM2OCCxZjCwMlAxPjlizszN MmrhNlQ6ODB6M{G=
KARPAS299 NXPwbmtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXy3NkBp NEPJ[mZFVVOR MXTJR|UxKG:oIECuNkDPxE1? NGe5cYUzPDlyMEizNS=>
NB1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlOwTWM2OD17MT65PEBvVQ>? MW\TRW5ITVJ?
NCI-SNU-5 M3PyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFyNT63OUBvVQ>? NFPhcYdUSU6JRWK=
SR MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjxOW1IUUN3ME2xNlYvOzFibl2= NVTKcnBmW0GQR1XS
SF539 NGLBVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJyND6yOEBvVQ>? M1\FUnNCVkeHUh?=
SU-DHL-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\QN2lEPTB;M{O2MlgzKG6P MlvIV2FPT0WU
SCC-3 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTN3Nj63OkBvVQ>? NUXuRXdPW0GQR1XS
DEL MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLxTWM2OD1|NkmuPUBvVQ>? MVTTRW5ITVJ?
CTV-1 NF31PGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTV7Nj60PEBvVQ>? MnXsV2FPT0WU
EM-2 M4q1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTZyMT6zOEBvVQ>? NUW0XodUW0GQR1XS
MHH-CALL-2 MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHriRYlKSzVyPU[4Nk42PyCwTR?= MXHTRW5ITVJ?
KM12 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2mybGlEPTB;N{C2Mlkhdk1? Mnf0V2FPT0WU
KINGS-1 NFLrc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2joS2lEPTB;N{S5Mlc2KG6P NVHpclljW0GQR1XS
MEG-01 M2LaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3niNmlEPTB;OEW3MlY3KG6P NXTCOlNtW0GQR1XS
BV-173 NYPOWplST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHmZXpKSzVyPUGuNFU6QTdizszN MX3TRW5ITVJ?
LAMA-84 M3vTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj4SYNKSzVyPUGuN|gzQDJizszN NE\RTI5USU6JRWK=
KARPAS-299 MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjGN2pKSzVyPUGuOFA5PjFizszN NIn2PWxUSU6JRWK=
K-562 NXnabmtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO5N2VxUUN3ME2xMlczOjZ7IN88US=> NFvZOm9USU6JRWK=
SK-LMS-1 NFPVXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DSSWlEPTB;MT63Olg3PyEQvF2= NGLFTGVUSU6JRWK=
MOLT-16 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7wTWM2OD1zLkm1OVc2KM7:TR?= NEfkXmNUSU6JRWK=
CMK MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC0TWM2OD1zLkm2NVU6KM7:TR?= NFjxPI9USU6JRWK=
ST486 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJwNEOwO|Mh|ryP Mmq1V2FPT0WU
CI-1 NGi4eYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrpXGtKSzVyPUKuOFk3PTlizszN M3nJWnNCVkeHUh?=
KP-N-RT-BM-1 M2njTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17HdGlEPTB;Mj63NFEzOiEQvF2= NUSxXHNQW0GQR1XS
ALL-PO MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n1NWlEPTB;Mz6xPFIxPyEQvF2= MVvTRW5ITVJ?
KS-1 Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTNwMkGyNlUh|ryP MWTTRW5ITVJ?
Becker MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTRwMkO5N{DPxE1? MYXTRW5ITVJ?
GDM-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHUbmFKSzVyPUSuNlQ3OTdizszN NGfOXIxUSU6JRWK=
BC-1 NF:0N3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnlNYxyUUN3ME20MlQ6Ojd5IN88US=> M1TiRnNCVkeHUh?=
NB14 NH;BblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fafmlEPTB;ND64N|UzPCEQvF2= M1jycXNCVkeHUh?=
NOS-1 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFezfXJKSzVyPUWuN|M5PzRizszN NXPTO2c4W0GQR1XS
MZ1-PC NVPCT3VPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TsZ2lEPTB;NT64NlE2OSEQvF2= M{XZOnNCVkeHUh?=
A498 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTZwMEi0O|Mh|ryP NWOzV25yW0GQR1XS
EW-16 Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTZwM{e3O|Mh|ryP MlHqV2FPT0WU
NALM-6 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni3TWM2OD14Lk[4N|g4KM7:TR?= MkPZV2FPT0WU
EB-3 NITaSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTdwMEeyN|Mh|ryP NF\2c4FUSU6JRWK=
697 MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmW5TWM2OD17LkK0N|I6KM7:TR?= MWfTRW5ITVJ?
Ramos-2G6-4C10 Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:1TWM2OD17LkW5PFQzKM7:TR?= MVLTRW5ITVJ?
KNS-81-FD NWfYTXVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPGfYhKSzVyPUmuOlk3PTNizszN MY\TRW5ITVJ?
HUTU-80 NWHtXo5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPrV5JKSzVyPUmuO|Q3PDJizszN NVPDXXR3W0GQR1XS
LS-411N M3zZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX1e25ZUUN3ME2xNE4xPTZ5IN88US=> NFeyTWRUSU6JRWK=
RPMI-8402 MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe3W2tKSzVyPUGwMlEyPiEQvF2= MlTOV2FPT0WU
KU812 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFyLkK5PVEh|ryP MoTSV2FPT0WU
EW-1 M3jQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFyLkS0NlUh|ryP NHnmTnhUSU6JRWK=
HC-1 NHPUOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrEZlNGUUN3ME2xNE41QDR2IN88US=> M3zLVnNCVkeHUh?=
NB69 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGqyPWtKSzVyPUGwMlUxPDNizszN Mor3V2FPT0WU
MFH-ino NFS0UoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXsOpJbUUN3ME2xNE45OzB|IN88US=> MmHTV2FPT0WU
CCRF-CEM MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe1fItbUUN3ME2xNU42QTdizszN MonzV2FPT0WU
SK-N-DZ NGDEN|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF{LkC0N|Yh|ryP NXzWWmJDW0GQR1XS
NCI-H720 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzmTWM2OD1zMj6xO|A2KM7:TR?= NHvzW49USU6JRWK=
HCC1187 M2XBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC2ZnRjUUN3ME2xNk4zODRzIN88US=> NWLEdmJOW0GQR1XS
IST-SL2 M{m2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;tVmlEPTB;MUKuOFg4OiEQvF2= MmfiV2FPT0WU
KE-37 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv3TIpTUUN3ME2xNk44QTZ4IN88US=> MlnJV2FPT0WU
HCC1599 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DhNmlEPTB;MUKuPVA3QSEQvF2= M4CzXXNCVkeHUh?=
A4-Fuk M{fweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF{Lkm1PFYh|ryP NVzObFZHW0GQR1XS
NKM-1 NIfQNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzLOm9IUUN3ME2xN{4zQTJ3IN88US=> NH7MZYxUSU6JRWK=
BE-13 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF|Lke5PFkh|ryP MYDTRW5ITVJ?
MV-4-11 MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TYbmlEPTB;MUSuNFMzPCEQvF2= NGK5eXpUSU6JRWK=
OPM-2 M4X0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LJPWlEPTB;MUSuOFA5PSEQvF2= NXnwW2tDW0GQR1XS
KARPAS-422 Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTF2LkWxNlYh|ryP MYTTRW5ITVJ?
RPMI-8226 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF2Lki5NVUh|ryP NGHDfVlUSU6JRWK=
KARPAS-45 Mo\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlziTWM2OD1zNT63O|E3KM7:TR?= MoX2V2FPT0WU
SK-PN-DW NWDRVWFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF3Lki2N|Eh|ryP MWjTRW5ITVJ?
LC-2 Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljHTWM2OD1zNj6xOVA3KM7:TR?= MmHEV2FPT0WU
NCI-H1648 M1fSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHLOY1pUUN3ME2xOk4zPTRizszN M{HwV3NCVkeHUh?=
RL95-2 NEH3epVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf4TWM2OD1zNj6zPVc5KM7:TR?= Mk\WV2FPT0WU
KNS-42 NWPzU3ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTF4LkeyO|Qh|ryP M{jhVXNCVkeHUh?=
RPMI-6666 NXfMSGxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Hs[mlEPTB;MU[uPVIyOSEQvF2= MYrTRW5ITVJ?
SIG-M5 M13UVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrrdVFKSzVyPUG3MlE6ODNizszN NIXyd2ZUSU6JRWK=
VA-ES-BJ M{XyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzGUlZ1UUN3ME2xO{44PDVzIN88US=> NXzHTYlYW0GQR1XS
MONO-MAC-6 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG5T45JUUN3ME2xO{46OzF{IN88US=> MYDTRW5ITVJ?
LAN-6 NVO3XlZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\kXmlEPTB;MUiuO|U2PyEQvF2= M4C5TXNCVkeHUh?=
A388 M2LYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTF7LkOwOVkh|ryP NYXYeHFiW0GQR1XS
SK-NEP-1 NEfr[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom4TWM2OD1{MD6yNVMzKM7:TR?= NH;oUFRUSU6JRWK=
TE-10 NECxbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDxUJlUUUN3ME2yNE42OjJzIN88US=> Ml\MV2FPT0WU
HL-60 NV;JU3JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJyLkmwPVkh|ryP MkHSV2FPT0WU
MC116 NYfRNnJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nNR2lEPTB;MkGuO|IzOSEQvF2= M{[yW3NCVkeHUh?=
SW962 NXjZR|lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;YSmlEPTB;MkGuO|kyPSEQvF2= MoPCV2FPT0WU
NOMO-1 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;GOI9CUUN3ME2yNk43PTZ2IN88US=> NXuwZXNHW0GQR1XS
CTB-1 MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjHTWM2OD1{Mj64OlcyKM7:TR?= NIjS[FdUSU6JRWK=
MRK-nu-1 MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W2c2lEPTB;MkKuPVA4PCEQvF2= MojQV2FPT0WU
GR-ST NVzJSIhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPVT5o4UUN3ME2yN{44PiEQvF2= MoTEV2FPT0WU
HH M1nkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ2LkCwN{DPxE1? MXfTRW5ITVJ?
NCI-H1963 NI\3fXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPweYZTUUN3ME2yOE4xPzh{IN88US=> MUHTRW5ITVJ?
QIMR-WIL NHHzco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT5O4d2UUN3ME2yOE45Pzd{IN88US=> NWLTU4d6W0GQR1XS
CGTH-W-1 M{PneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInlPGZKSzVyPUK1MlA4OjNizszN NE\oWIlUSU6JRWK=
LP-1 NHrWOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ3Lk[1OVEh|ryP M2DBSXNCVkeHUh?=
NCI-H748 NWrUW|ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJ4LkWxN|ch|ryP NIT3[4VUSU6JRWK=
PF-382 M4SySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ5LkKyNlMh|ryP NFf0ZWxUSU6JRWK=
ATN-1 M2K3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ5LkO3N|Ih|ryP MojpV2FPT0WU
L-540 NWe2UokzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjN[pJKSzVyPUK3MlY1PTlizszN MnnWV2FPT0WU
LXF-289 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLYWlhsUUN3ME2yO{44PTF7IN88US=> NGTmelRUSU6JRWK=
LS-513 NW\wd4I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfNTYZyUUN3ME2yPE4yQDB5IN88US=> MofNV2FPT0WU
NCI-H1581 M4jNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojuTWM2OD1|MD6zPVc3KM7:TR?= MXrTRW5ITVJ?
ES6 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\Ue2lEPTB;M{CuOlg6QSEQvF2= NU\Dbo84W0GQR1XS
SW982 M1nrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LvW2lEPTB;M{CuPFU3PiEQvF2= NIr5W41USU6JRWK=
DOHH-2 M17OUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTNzLkW4PVMh|ryP NEfXbXZUSU6JRWK=
DB MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTN|Lkm0N|Eh|ryP NFHabZNUSU6JRWK=
MPP-89 M1PYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTN2LkG3OVYh|ryP M4TtV3NCVkeHUh?=
LB831-BLC NHexNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETLW3hKSzVyPUO0MlUyQDRizszN M1rMZnNCVkeHUh?=
NB5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\mUJllUUN3ME2zOE45PTN3IN88US=> MXPTRW5ITVJ?
GB-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[5R2lwUUN3ME2zOU4xPDZ7IN88US=> NXjzRXRSW0GQR1XS
TE-15 NEiySFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\KTWM2OD1|NT6yNlM5KM7:TR?= M4ewUXNCVkeHUh?=
LC4-1 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fiVmlEPTB;M{WuN|g1PyEQvF2= NYjVVmNMW0GQR1XS
NCI-H747 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXHTWM2OD1|Nj6xN|Y6KM7:TR?= NVq1RYlKW0GQR1XS
NTERA-S-cl-D1 M2\hZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTN6LkezOFch|ryP NUjGSJRSW0GQR1XS
SK-MM-2 NGXETZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH0TWM2OD12MD6xNVQ3KM7:TR?= MnPMV2FPT0WU
TGW MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:1e2lEPTB;NEGuNFU3OyEQvF2= M{TuUHNCVkeHUh?=
ONS-76 MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTMVoRKSzVyPUSyMlQ5QDNizszN MmiyV2FPT0WU
CPC-N M4TQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTR{Lkm5O|Eh|ryP NYTSWnBUW0GQR1XS
ES4 NIfSfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTR2LkSxOVMh|ryP MnrMV2FPT0WU
Daudi NF[zNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPjfIF6UUN3ME20OU4xQDJ5IN88US=> NXW4VYdXW0GQR1XS
MOLT-4 M4jRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS2OmE3UUN3ME20OU4xQDV|IN88US=> M4\JdnNCVkeHUh?=
HT-144 MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S4VmlEPTB;NE[uO|I3KM7:TR?= MmmxV2FPT0WU
SW872 NFHPXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fydWlEPTB;NEiuNVk{OyEQvF2= Mmq3V2FPT0WU
D-283MED Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTR6LkO1OFIh|ryP M2XWVnNCVkeHUh?=
NCI-H2126 NIG2SpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTR6Lki0O|Yh|ryP MVTTRW5ITVJ?
NCI-SNU-16 NGDRfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH2eXlmUUN3ME20PU4zOTR|IN88US=> M4q5[XNCVkeHUh?=
CESS NHuxfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DpVmlEPTB;NEmuOVA5QCEQvF2= NXG5WVFqW0GQR1XS
A101D NIHaUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfKTWM2OD12OT65O|M3KM7:TR?= NXeyXnM1W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pALK / pAKT / pERK / pS6; 

PubMed: 24675041     


H3122 cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins.

pROS1 / ROS1; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.

pSTAT3 / STAT3; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.

PARP / cleaved caspase-3 / Bax / Bcl-2; 

PubMed: 25193856     


The expression of PARP, cleaved caspase-3, Bax, and Bcl-2 were measured by western blotting after PANC-1 cells were treated with various concentrations of Crizotinib (0-10 μM) for 72 hr.

p-c-Met / c-Met; 

PubMed: 25193856     


Cancer cells with c-MET alterations were exposed to Crizotinib (10 μM) in the indicated times (SNU-5, MKN-45, and SNU-638: gastric cancer cells of c-MET amplification).

p-mTOR; 

PubMed: 26384345     


Immunoblotting for phospho- or total MET, STAT3, AKT, MTOR and ERK in SPC-A1 cells treated with crizotinib for 48 h.

24675041 25351743 25193856 26384345
Immunofluorescence
LC3 / lysosome; 

PubMed: 26384345     


Cells were treated with DMSO or 4 μM crizotinib for 72 h before they were labeled with a fluorescent marker and imaged by fluorescence microscopy. Green: FITC-labeled LC3; Red: lyso-tracker-labeled lysosome; Blue: DAPI-labeled nucleus. 

SRC / Met; 

PubMed: 26517812     


Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in (A) LN-18 and (B) U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

α-tubulin; 

PubMed: 26517812     


LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

cytochrome c; 

PubMed: 25193856     


PANC-1 pancreatic cancer cells were treated with Crizotinib (1 and 10 μM) for 6 hr and stained with anti-cytochrome c antibody, Mitotracker and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification. Cytochrome c (green), mitotracker: red

p-ALK; 

PubMed: 25193856     


PANC-1 cells were also treated with various concentrations (0-10 μM) of Crizotinib and stained with p-ALK antibody and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification.

26384345 26517812 25193856
体内研究

PF-2341066每天按50 mg/kg和75 mg/kg剂量处理GTL-16 模型, 引起大肿瘤 (体积大于600 mm3) 明显衰退,且按43天处理日程处理后,平均肿瘤体积降低60%。在另一项研究中, PF-2341066处理3个月以上,完全抑制GTL-16肿瘤生长,PF-2341066每天按50 mg/kg剂量处理小鼠,3个月后,只有1/12小鼠的肿瘤生长得到提高。PF-2341066每天按50 mg/kg剂量处理NCI-H441 NSCLC 模型处理周期为38天,观察到平均肿瘤体积降低43%。PF-2341066 每天按50 mg/kg剂量作用于 Caki-1 RCC模型,处理周期为33天,观察到平均肿瘤体积降低53%,且每种肿瘤体积降低至少30%。PF-2341066每天按 50 mg/kg剂量作用于 U87MG 恶性胶质瘤或PC-3前列腺癌移植瘤模型,几乎完全抑制肿瘤生长,在实验最后一天,抑制分别达97% 或84%。相反, PF-2341066每天按50 mg/kg剂量口服给药处理 MDA-MB-231 乳腺癌模型,或 DLD-1 结肠癌模型,不会显著抑制肿瘤生长。PF-2341066每天按12.5 mg/kg, 25 mg/kg, 和50 mg/kg剂量作用于 GTL-16 肿瘤,观察到CD31阳性内皮细胞显著降低,这种作用存在剂量依赖性,说明 MVD 受抑制,且具有相关的抗癌高效性,这种作用也存在剂量依赖性。PF-2341066 作用于GTL-16 和 U87MG 模型,显著降低人VEGFA 和IL-8血浆水平,这种作用存在剂量依赖性。PF-2341066口服处理GTL-16 肿瘤,观察到磷酸化的c-Met, Akt, Erk, PLCλ1,和 STAT5水平显著受抑制。[1]PF-2341066 每天按100 mg/kg剂量口服处理携带Karpas299 ALCL 移植瘤的SCID Beige 小鼠,具有抗癌高效性,这种作用存在剂量依赖性,处理15天,所有肿瘤完全衰退。此外, PF-2341066抑制关键NPM-ALK信号调节器, 包括磷脂酶C-γ, 信号转导器,及转录因子3, 细胞外信号调节激酶, 和Akt的激活剂,这些与 NPM-ALK 磷酸化和功能受抑制相关。[2] PF-2341066 抑制骨肉瘤的一些活动行为,及其肿瘤生长(例如, 增殖和存活)和转移 (例如,入侵和形成克隆)。PF-2341066口服饲喂裸鼠,抑制生长和相关的骨肉瘤裸鼠移植瘤的骨基质的形成。[3] PF-2341066 按50 mg/kg 剂量处理 c-MET-扩增的GTL-16移植瘤,引起肿瘤衰退,这与18F-FDG 摄取的缓慢降低相关,且降低葡糖糖转运蛋白 1, GLUT-1的表达。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

生化激酶实验:

使用连续耦合的分光光度测定c-Met催化活性,通过分析NADH消耗率而测定c-Met诱导的ADP产量,这种作用具有时间依赖性。在 340 nm处使用分光光度法在指定时间点测定吸光值的降低而计算NADH的消耗量。为了测定Ki值, 在含实验试剂的实验孔中加入不同浓度PF-2341066,然后在37oC下温育10分钟。加入c-Met酶开始进行实验反应。
细胞实验:

[1]

- 合并
  • Cell lines: GTL-16胃癌细胞和T47D乳腺癌细胞
  • Concentrations: 0 nM-256 nM
  • Incubation Time: 1小时
  • Method:

    GTL-16胃癌细胞和T47D乳腺癌细胞接种在96孔板上,孔中含培养基,培养基中含10% 胎牛血清(FBS),然后转移到无血清培养基中[含0.04%牛血清蛋白(BSA)],处理 24小时。 在调查配体依赖的RTK 磷酸化实验中,加入相应的生长因子,处理20分钟。细胞和 PF-2341066和/或适当配体在指定时间温育1小时,然后使用含 1 mmol/L Na3VO4的HBSS冲洗细胞一次,然后从细胞中获得蛋白裂解物。随后,通过夹心酶联免疫吸附试验法使用特定的捕获抗体在96孔板上测定选定蛋白激酶的磷酸化,使用特点检测抗体测定磷酸化的酪氨酸残基。抗体包被的实验板(a) 在蛋白裂解物存在时,在4oC下过夜;(b)在溶于PBS的1% Tween-20 中冲洗7次;(c)在辣根过氧化物酶标记的抗总磷酸(PY-20)抗体(1:500)中温育20分钟;(d) 再次冲洗7次;(e)在3,3,5,5-四甲基联苯胺过氧化物酶底物中温育,开始显示反应,加入0.09 N H2SO4终止反应; (f)在450 nm 处使用分光光度计测定吸光度。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 携带NCI-H441,或DLD-1,或MDA-MB-231的雌性和雄性nu/nu小鼠
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 和50 mg/kg/day
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+dd H2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 450.34
化学式

C21H22Cl2FN5O

CAS号 877399-52-5
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04148066 Recruiting Diagnostic Test: ctDNA blood sample Carcinoma Non-Small-Cell Lung The Netherlands Cancer Institute|Roche Pharma AG July 17 2019 Phase 2
NCT03439215 Recruiting Drug: Lorlatinib Carcinoma Non-Small-Cell Lung Fondazione Ricerca Traslazionale|Clinical Research Technology S.r.l. June 13 2017 Phase 2
NCT02946216 Unknown status Genetic: ctDNA analysis Non-small Cell Lung Cancer Stage III|Non-Small-Cell Lung Cancer Metastatic|Adenocarcinoma of Lung|EGFR Wildtype First People''s Hospital of Hangzhou November 2016 --
NCT02511184 Terminated Drug: Crizotinib|Drug: Pembrolizumab ALK-positive Advanced NSCLC Pfizer|Merck Sharp & Dohme Corp. October 2015 Phase 1
NCT02419287 Unknown status Drug: crizotinib Anaplastic Large Cell Lymphoma ALK-Positive University of Milano Bicocca April 2015 Phase 2
NCT02499614 Unknown status Drug: Crizotinib Carcinoma Non-Small-Cell Lung Fondazione Ricerca Traslazionale December 2014 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • 回答:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品

Tags: 购买Crizotinib (PF-02341066) | Crizotinib (PF-02341066)供应商 | 采购Crizotinib (PF-02341066) | Crizotinib (PF-02341066)价格 | Crizotinib (PF-02341066)生产 | 订购Crizotinib (PF-02341066) | Crizotinib (PF-02341066)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID